The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - Johnson & Johnson; Lilly; Medtronic; Takeda
Research Funding - AMCO (Inst); Medtronic (Inst); Stryker (Inst); TERUMO (Inst)
Clinical validation of plasma circulating-tumor DNA assay using highly sensitive Safe-SeqS technology for detecting RAS and BRAF V600E in metastatic colorectal cancer.
 
Yu Miyashita
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Jun Watanabe
No Relationships to Disclose
 
Yusuke Suwa
No Relationships to Disclose
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical; Takeda Science Foundation
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Hiroko Hasegawa
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Masako Asayama
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Isofol Medical (Inst); SYSMX (Inst)
 
Tomohiro Nishina
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akira Inoue
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Hiroya Taniguchi
Honoraria - Amgen; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Yakuhin; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Takashi Ohta
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; EA Pharma; Lilly Japan; Merck KGaA; Novartis; Taiho Pharmaceutical; Takeda
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Hiromichi Nakajima
Employment - Otsuka (I)
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Koji Yamamoto
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)